Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

From a shot to a spray?
May 2020
SHARING OPTIONS:

RALEIGH, N.C.—According to Bryn Pharma, LLC, preclinical canine studies have suggested that intranasal (IN) epinephrine administration could offer faster absorption in histamine-induced nasal congestion, which is common during anaphylactic episodes. The company was evaluating epinephrine pharmacokinetics and heart rate in the studies, and results were published online in Respiratory Research. IN epinephrine resulted in a greater peak epinephrine concentration vs. saline, as well as a shorter time to reach maximum concentration—six minutes vs. 70 minutes, respectively. Epinephrine is the standard treatment for anaphylaxis, but most people at risk for severe allergic reactions do not carry the recommended two epinephrine auto-injectors due to cost and size. In addition, injuries, fear of needles and administration anxiety are noted obstacles for this delivery method. Bryn is seeking to address this issue with its Bi-Dose Epinephrine Nasal Spray, which delivers two therapeutic doses.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.